{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:38:17Z","timestamp":1794775097312,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blood biomarkers indicative of Alzheimer\u2019s disease (AD) pathology are altered in both preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the identification of AD pathology or monitoring of disease progression. Blood biomarkers that correlate with changes in cognition and atrophy during the course of the disease could be used in clinical trials to identify successful interventions and thereby accelerate the development of efficient therapies. When disease-modifying treatments become approved for use, efficient blood-based biomarkers might also inform on treatment implementation and management in clinical practice. In the BioFINDER-1 cohort, plasma phosphorylated (p)-tau231 and amyloid-\u03b242\/40 ratio were more changed at lower thresholds of amyloid pathology. Longitudinally, however, only p-tau217 demonstrated marked amyloid-dependent changes over 4\u20136\u2009years in both preclinical and symptomatic stages of the disease, with no such changes observed in p-tau231, p-tau181, amyloid-\u03b242\/40, glial acidic fibrillary protein or neurofilament light. Only longitudinal increases of p-tau217 were also associated with clinical deterioration and brain atrophy in preclinical AD. The selective longitudinal increase of p-tau217 and its associations with cognitive decline and atrophy was confirmed in an independent cohort (Wisconsin Registry for Alzheimer\u2019s Prevention). These findings support the differential association of plasma biomarkers with disease development and strongly highlight p-tau217 as a surrogate marker of disease progression in preclinical and prodromal AD, with impact for the development of new disease-modifying treatments.<\/jats:p>","DOI":"10.1038\/s41591-022-02074-w","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:29:21Z","timestamp":1669901361000},"page":"2555-2562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":420,"title":["Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring"],"prefix":"10.1038","volume":"28","author":[{"given":"Nicholas J.","family":"Ashton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-3337","authenticated-orcid":false,"given":"Alexa Pichet","family":"Binette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner S.","family":"Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fern\u00e1ndo","family":"Gonz\u00e1lez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Di Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3343-7351","authenticated-orcid":false,"given":"Francisco J.","family":"Meda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Jonaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-744X","authenticated-orcid":false,"given":"Rebecca Langhough","family":"Koscik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-2560","authenticated-orcid":false,"given":"Karly","family":"Cody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8856-1352","authenticated-orcid":false,"given":"Tobey J.","family":"Betthauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5366","authenticated-orcid":false,"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-545X","authenticated-orcid":false,"given":"Sterling C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"2074_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"2074_CR2","doi-asserted-by":"publisher","unstructured":"Hansson O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12756 (2022).","DOI":"10.1002\/alz.12756"},{"key":"2074_CR3","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"2074_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-beta 42\/40 assays in Alzheimer disease. JAMA Neurol. 78, 1375\u20131382 (2021).","journal-title":"JAMA Neurol."},{"key":"2074_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathol."},{"key":"2074_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"2074_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"2074_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"2074_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"2074_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K. & Alzheimer\u2019s Disease Neuroimaging Initiative Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557\u2013566 (2017).","journal-title":"JAMA Neurol."},{"key":"2074_CR11","doi-asserted-by":"crossref","unstructured":"Pereira J. B. et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease. Brain 144, 3505\u20133516 (2021).","DOI":"10.1093\/brain\/awab223"},{"key":"2074_CR12","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471\u20131483 (2021).","journal-title":"JAMA Neurol."},{"key":"2074_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"2074_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez, J. et al. Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 140, 267\u2013278 (2020).","journal-title":"Acta Neuropathol."},{"key":"2074_CR15","doi-asserted-by":"crossref","unstructured":"Smirnov D. S. et al. Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 143, 487\u2013503 (2022).","DOI":"10.1007\/s00401-022-02408-5"},{"key":"2074_CR16","doi-asserted-by":"publisher","unstructured":"Salvad\u00f3 S. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and neurofibrillary tau tangle loads. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.08.22.22279052 (2022).","DOI":"10.1101\/2022.08.22.22279052"},{"key":"2074_CR17","doi-asserted-by":"crossref","unstructured":"Meyer P. F. et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann. Neurol. 91, 548\u2013560 (2022).","DOI":"10.1002\/ana.26308"},{"key":"2074_CR18","doi-asserted-by":"crossref","unstructured":"Mila-Aloma M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","DOI":"10.1038\/s41591-022-01925-w"},{"key":"2074_CR19","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241 (2020).","journal-title":"Brain"},{"key":"2074_CR20","doi-asserted-by":"crossref","unstructured":"Janelidze, S. et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma Abeta42\/Abeta40 and p-tau. Alzheimers Dement. 18, 283\u2013293 (2022).","DOI":"10.1002\/alz.12395"},{"key":"2074_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"2074_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1\u201315 e11-14 (2015).","journal-title":"Alzheimers Dement."},{"key":"2074_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40478-021-01307-2","volume":"10","author":"M Wennstrom","year":"2022","unstructured":"Wennstrom, M. et al. Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta Neuropathol. Commun. 10, 3 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"2074_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791\u2013799 (2019).","journal-title":"JAMA Neurol."},{"key":"2074_CR25","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1093\/brain\/awaa342","volume":"143","author":"AL Benedet","year":"2020","unstructured":"Benedet, A. L. et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer\u2019s disease. Brain 143, 3793\u20133804 (2020).","journal-title":"Brain"},{"key":"2074_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","volume":"143","author":"SA Kaeser","year":"2022","unstructured":"Kaeser, S. A. et al. CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 143, 287\u2013290 (2022).","journal-title":"Acta Neuropathol."},{"key":"2074_CR27","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren, N. et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol. Med. 13, e14022 (2021).","journal-title":"EMBO Mol. Med."},{"key":"2074_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol."},{"key":"2074_CR29","doi-asserted-by":"crossref","unstructured":"Karikari T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","DOI":"10.1038\/s41582-022-00665-2"},{"key":"2074_CR30","doi-asserted-by":"crossref","unstructured":"Leuzy A. et al. Comparing the clinical utility and diagnostic performance of cerebrospinal fluid p-tau181, p-tau217 and p-tau231 assays. Neurology 97, e1681\u2013e1694 (2021).","DOI":"10.1212\/WNL.0000000000012727"},{"key":"2074_CR31","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine 76, 103836 (2022).","journal-title":"EBioMedicine"},{"key":"2074_CR32","doi-asserted-by":"crossref","unstructured":"Pontecorvo M. J. et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. Preprint at https:\/\/pubmed.ncbi.nlm.nih.gov\/36251300\/ (2022).","DOI":"10.1001\/jamaneurol.2022.3392"},{"key":"2074_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy, S. et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res. Ther. 13, 198 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"2074_CR34","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","journal-title":"J. Exp. Med."},{"key":"2074_CR35","doi-asserted-by":"crossref","unstructured":"Schindler S. E. et al. Effect of race on prediction of brain amyloidosis by plasma Abeta42\/Abeta40, phosphorylated tau, and neurofilament light. Neurology 99, e245\u2013e257 (2022).","DOI":"10.1212\/WNL.0000000000200358"},{"key":"2074_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman, A. M. et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 17, 1353\u20131364 (2021).","journal-title":"Alzheimers Dement."},{"key":"2074_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10918","volume":"7","author":"N Mattsson","year":"2016","unstructured":"Mattsson, N. et al. Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis. Nat. Commun. 7, 10918 (2016).","journal-title":"Nat. Commun."},{"key":"2074_CR38","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"2074_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"2074_CR40","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. (N. Y.) 3, 668\u2013677 (2017).","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"2074_CR41","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322\u2013e333 (2019).","journal-title":"Neurology"},{"key":"2074_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.dadm.2017.11.007","volume":"10","author":"SC Johnson","year":"2018","unstructured":"Johnson, S. C. et al. The Wisconsin Registry for Alzheimer\u2019s Prevention: a review of findings and current directions. Alzheimers Dement. (Amst.) 10, 130\u2013142 (2018).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"2074_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.dadm.2018.11.006","volume":"11","author":"EM Jonaitis","year":"2019","unstructured":"Jonaitis, E. M. et al. Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement. (Amst.) 11, 74\u201384 (2019).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"2074_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr.","year":"2017","unstructured":"Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"2074_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","volume":"183","author":"P Bourgeat","year":"2018","unstructured":"Bourgeat, P. et al. Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL. Neuroimage 183, 387\u2013393 (2018).","journal-title":"Neuroimage"},{"key":"2074_CR46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2013.09.028","volume":"35","author":"SC Johnson","year":"2014","unstructured":"Johnson, S. C. et al. Amyloid burden and neural function in people at risk for Alzheimer\u2019s Disease. Neurobiol. Aging 35, 576\u2013584 (2014).","journal-title":"Neurobiol. Aging"},{"key":"2074_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/brain\/awz378","volume":"143","author":"TJ Betthauser","year":"2020","unstructured":"Betthauser, T. J. et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain 143, 320\u2013335 (2020).","journal-title":"Brain"},{"key":"2074_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.dadm.2015.11.006","volume":"2","author":"AM Racine","year":"2016","unstructured":"Racine, A. M. et al. Cerebrospinal fluid ratios with Abeta42 predict preclinical brain beta-amyloid accumulation. Alzheimers Dement. (Amst.) 2, 27\u201338 (2016).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"2074_CR49","doi-asserted-by":"crossref","unstructured":"Papp K. V. et al. Association of emerging beta-amyloid and tau pathology with early cognitive changes in clinically normal older adults. Neurology 98, e1512\u2013e1524 (2022).","DOI":"10.1212\/WNL.0000000000200137"},{"key":"2074_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvado","year":"2019","unstructured":"Salvado, G. et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res. Ther. 11, 27 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"2074_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 15, 205\u2013216 (2019).","journal-title":"Alzheimers Dement."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02074-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02074-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02074-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T11:04:10Z","timestamp":1672571050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02074-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2074"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02074-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"24 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.A. has given lectures in symposia sponsored by Eli Lilly. S.J. has no disclosures. N.M.-C. has no disclosures. A.P.B. has no disclosures. O.S. has no disclosures. W.S.B. has no disclosures. T.K.K. has no disclosures. F.G.-O. has no disclosures. G.D.M. has no disclosures. F.J.M. has no disclosures. E.M.J. has no disclosures. R.L.K. has no disclosures. K.C. has no disclosures. T.J.B. has no disclosures. Y.L. has no disclosures. E.V. is a cofounder of ADx Neurosciences. S.P. has served on scientific advisory boards and\/or given lectures in symposia sponsored by Biogen, Eli Lilly, Geras Solutions and Roche. E.S. has no disclosures. R.J.B. has equity ownership interest in C2N Diagnostics and may receive income based on technology licensed or optioned by Washington University to C2N Diagnostics, receives income from C2N Diagnostics for serving on the scientific advisory board and has received honoraria as a speaker\/consultant\/advisory board member from Amgen, Eisai and Roche. H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). S.C.J. has within the past 3\u2009years served at scientific advisory boards and\/or as a consultant for Roche Diagnostics, Prothena and Eisai and has received research support from Cerveau Technologies. K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2\u2009years, he has received consultancy\/speaker fees from Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche and Siemens.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}